Radiopharma 2025–2028: an executive view for boards and CEOs.

ASEAN stands at a turning point in radiopharma. Cancer, cardiac, and neurological cases are rising sharply, yet access to PET/CT scans and tracers remains uneven. Cyclotrons exist in a few hubs, while many countries still rely on unstable imports and ad-hoc supply chains.

The opportunity is clear: radiopharma is infrastructure. Mature markets run predictable PET networks with reliable first-dose availability. In contrast, developing ASEAN markets face thin GMP capability, scarce talent, patchy logistics, and slow multi-agency approvals. Value will be created by localising production where volumes justify it, anchoring distribution to flagship hospitals, and embedding theranostics readiness from the outset.

Cyclotrons, PET, and theranostics are moving from pilots to mainstream service lines across ASEAN. Capital is available, vendors are ready, regulators are clearer. But execution remains the choke point. Too many projects slip 6–12 months because they are treated like standard imaging installs. Winners will be those who run cyclotrons as pharmaceutical plants, build bankable operations, and deliver first dose on time.

Hard truths

Hardware isn't the bottleneck — people and integration are. Success depends on an integrated team that runs end to end, from feasibility to operations, aligned to a single baseline financial model. If scope, validation, or operations drift, approvals lag and first dose slips.

Bankability depends on a living, integrated model — not a slide deck. Investors and lenders back projects where every line item is traceable: utilities, shielding, cleanroom specs, validation scope, staffing, uptime targets, referral volumes. Discipline comes from a model linked directly to SOPs, contracts, and the Validation Master Plan.

Theranostics readiness must be built in. PET supply, pharmacy throughput, QC capacity, protection protocols and discharge rules all drive cost, utilisation, and unit economics. If not modelled early, bottlenecks emerge downstream.

Cyclotrons are not MRIs or CTs. They are GMP pharmaceutical plants with cleanrooms, hot cells, validated processes, batch release, radiation safety, and waste protocols. Economically, they behave like infrastructure: large upfront capex, steady but moderate cash flows, and long payback periods. They require strategic commitment, not opportunistic bets.

Utilisation economics make or break the P&L. Uptime, throughput, and process discipline are everything. Preventive maintenance, critical spares, calibrated instruments, and strict SOPs protect profit. Beam time scheduling, QC turnaround, and last-mile logistics must run to the minute.

Partnerships are decisive. Vendors, logistics providers, and hospitals must be tightly orchestrated. Interfaces, SLAs, permits, cold chain, discharge protocols, and clinic cut-offs all need precision. Without coordination, the last mile breaks the P&L.

Race to first dose

The competitive edge lies in reaching first dose reliably. That means:

  • Building hub-and-spoke models anchored to key stakeholders — ministries, hospital groups, private diagnostics — and an anchor hospital.
  • Securing trusted equipment/EPC and logistics partners early, with clear SLAs and escalation paths.
  • Embedding service design around therapy-first workflows — mapping indication-led pathways, aligning protocols to throughput limits, and only adding isotopes once the baseline runs clean.
  • Treating data as an operating asset from day one — tracking utilisation, yields, costs, and uptime to continuously validate and adjust the model.

Conclusion

Radiopharma in ASEAN is an infrastructure play, not an equipment race. The leaders won't be those first to sign a purchase order. They will be the ones who align governance, partners, and people around a living model, validate like pharma, and deliver first dose on time — consistently.

For boards and CEOs, the decision is not about whether radiopharma will grow. It will. The question is whether your organisation will be among the first to deliver bankable, inspection-ready capacity and capture long-term value in the region.

At KPA, we specialise in nuclear medicine projects across ASEAN, advising from early planning and feasibility through licensing, GMP setup, and operations. Our experience spans cyclotrons, PET/CT, theranostics, and integrated imaging and treatment centres. Having led several of the region's first-of-its-kind cyclotron projects, we know what it takes to bridge strategy with execution and deliver inspection-ready facilities that create lasting value.